kwic
risk
risk
right
off
ON
257
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for risk out of >500 occurrences
421954 occurrences (No.40 in the rank) during 5 years in the PubMed. [cache]
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to risk]
421954 occurrences (No.40 in the rank) during 5 years in the PubMed. [cache]
| 257) Hypercholesterolemia is a well-known pro-atherogenic risk factor and statin is the most effective anti-atherogenic drug that lowers blood cholesterol levels. |
| PMID:34696890 DOI:10.1016/bs.ctm.2021.08.004 |
| 2021 Current topics in membranes |
| * Atorvastatin and blood flow regulate expression of distinctive sets of genes in mouse carotid artery endothelium. |
| - Hypercholesterolemia is a well-known pro-atherogenic risk factor and statin is the most effective anti-atherogenic drug that lowers blood cholesterol levels. However, despite systemic hypercholesterolemia, atherosclerosis preferentially occurs in arterial regions exposed to disturbed blood flow (d-flow), while the stable flow (s-flow) regions are spared. Given their predominant effects on endothelial function and atherosclerosis, we tested whether (1) statin and flow regulate the same or independent sets of genes and (2) statin can rescue d-flow-regulated genes in mouse artery endothelial cells in vivo. To test the hypotheses, C57BL/6 J mice (8-week-old male, n=5 per group) were pre-treated with atorvastatin (10mg/kg/day, Orally) or vehicle for 5 days. Thereafter, partial carotid ligation (PCL) surgery to induce d-flow in the left carotid artery (LCA) was performed, and statin or vehicle treatment was continued. The contralateral right carotid artery (RCA) remained exposed to s-flow to be used as the control. Two days or 2 weeks post-PCL surgery, endothelial-enriched RNAs from the LCAs and RCAs were collected and subjected to microarray gene expression analysis. Statin treatment in the s-flow condition (RCA+statin versus RCA+vehicle) altered the expression of 667 genes at 2-day and 187 genes at 2-week timepoint, respectively (P<0.05, fold change (FC)≥±1.5). Interestingly, statin treatment in the d-flow condition (LCA+statin versus LCA+vehicle) affected a limited number of genes: 113 and 75 differentially expressed genes at 2-day and 2-week timepoint, respectively (P<0.05, FC≥±1.5). In contrast, d-flow in the vehicle groups (LCA+vehicle versus RCA+vehicle) differentially regulated 4061 genes at 2-day and 3169 genes at 2-week timepoint, respectively (P<0.05, FC≥±1.5). Moreover, statin treatment did not reduce the number of flow-sensitive genes (LCA+statin versus RCA+statin) compared to the vehicle groups: 1825 genes at 2-day and 3788 genes at 2-week, respectively, were differentially regulated (P<0.05, FC≥±1.5). These results revealed that both statin and d-flow regulate expression of hundreds or thousands of arterial endothelial genes, respectively, in vivo. Further, statin and d-flow regulate independent sets of endothelial genes. Importantly, statin treatment did not reverse d-flow-regulated genes except for a small number of genes. These results suggest that both statin and flow play important independent roles in atherosclerosis development and highlight the need to consider their therapeutic implications for both. |
[
right
kwic]
(1)139  of |
(11)7 prediction |
(21)3 decision |
(31)2 markers |
| (2)49 factors |
(12)6 stratification |
(22)3 or |
(32)2 mitigation |
| (3)46 for |
(13)5 individuals |
(23)3 patients |
(33)2 population |
| (4)21 *null* | (14)4 genes |
(24)2 (OR |
(34)2 ratio |
| (5)19 factor |
(15)4 populations |
(25)2 among |
(35)2 reduction |
| (6)16 and |
(16)4 score |
(26)2 communication |
(36)2 screening |
| (7)13 assessment |
(17)4 to |
(27)2 communication, |
(37)2 strategies |
| (8)12 in |
(18)4 variants |
(28)2 designations |
|
| (9)8 perception |
(19)3 alleles |
(29)2 group |
|
| (10)7 factors, |
(20)3 assessment, |
(30)2 is |
add keyword
--- WordNet output for risk ---